Chemomab Therapeutics (CMMB) Projected to Post Earnings on Thursday

Chemomab Therapeutics (NASDAQ:CMMB) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Chemomab Therapeutics to post earnings of ($0.20) per share for the quarter.

Chemomab Therapeutics Stock Down 13.9 %

Shares of CMMB opened at $1.30 on Wednesday. Chemomab Therapeutics has a 12-month low of $0.58 and a 12-month high of $2.55. The firm has a market capitalization of $18.67 million, a price-to-earnings ratio of -1.30 and a beta of 0.66. The stock’s 50-day moving average price is $1.96 and its 200 day moving average price is $1.74.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Oppenheimer restated an “outperform” rating and set a $11.00 price target (down from $13.00) on shares of Chemomab Therapeutics in a research note on Friday, November 15th. Maxim Group boosted their price target on Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, February 20th.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).